Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
Open accessThe DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.
Abstract
BACKGROUND: All-trans retinoic acid (ATRA) with chemotherapy is the standard of care for acute promyelocytic leukemia (APL), resulting in cure rates exceeding 80%. Pilot studies of treatment with arsenic trioxide with or without ATRA have shown high efficacy and reduced hematologic toxicity. METHODS: We conducted a phase 3, multicenter trial comparing ATRA plus chemotherapy with ATRA plus arsenic trioxide in patients with APL classified as low-to-intermediate risk (white-cell count, ≤10×10(9) per liter). Patients were randomly assigned to receive either ATRA plus arsenic trioxide for induction and consolidation therapy or standard ATRA-idarubicin induction therapy followed by three cycles of consolidation therapy with ATRA plus chemotherapy and maintenance therapy with low-dose chemotherapy and ATRA. The study was designed as a noninferiority trial to show that the difference between the rates of event-free survival at 2 years in the two groups was not greater than 5%. RESULTS: Complete remission was achieved in all 77 patients in the ATRA-arsenic trioxide group who could be evaluated (100%) and in 75 of 79 patients in the ATRA-chemotherapy group (95%) (P=0.12). The median follow-up was 34.4 months. Two-year event-free survival rates were 97% in the ATRA-arsenic trioxide group and 86% in the ATRA-chemotherapy group (95% confidence interval for the difference, 2 to 22 percentage points; P<0.001 for noninferiority and P=0.02 for superiority of ATRA-arsenic trioxide). Overall survival was also better with ATRA-arsenic trioxide (P=0.02). As compared with ATRA-chemotherapy, ATRA-arsenic trioxide was associated with less hematologic toxicity and fewer infections but with more hepatic toxicity. CONCLUSIONS: ATRA plus arsenic trioxide is at least not inferior and may be superior to ATRA plus chemotherapy in the treatment of patients with low-to-intermediate-risk APL. (Funded by Associazione Italiana contro le Leucemie and others; ClinicalTrials.gov number, NCT00482833.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Bennett, J. M., Catovsky, D., Daniel, M., Flandrin, G., Galton, D. A. G., Gralnick, H. R., & Sultan, C. (1976) · British Journal of Haematology · doi:10.1111/j.1365-2141.1976.tb03563.x · Cited by 5,602
Cheson, B. D., Bennett, J. M., Kopecky, K. J., Büchner, T., Willman, C. L., Estey, E. H., Schiffer, C. A., Doehner, H., Tallman, M. S., Lister, T. A., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.036 · Cited by 2,654
Self-citationCreutzig, U., & Kaspers, G. J. L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.99.116 · Cited by 2,137
Thiede, C., Steudel, C., Mohr, B., Schaich, M., Schäkel, U., Platzbecker, U., Wermke, M., Bornhäuser, M., Ritter, M., Neubauer, A., et al. (2002) · Blood · doi:10.1182/blood.v99.12.4326 · Cited by 1,735
Self-citationShen, Z.-X., Chen, G.-Q., Ni, J.-H., Li, X.-S., Xiong, S.-M., Qiu, Q.-Y., Zhu, J., Tang, W., Sun, G.-L., Yang, K.-Q., et al. (1997) · Blood · doi:10.1182/blood.v89.9.3354 · Cited by 1,428
Gabert, J., Beillard, E., van der Velden, V. H. J., Bi, W., Grimwade, D., Pallisgaard, N., Barbany, G., Cazzaniga, G., Cayuela, J. M., Cavé, H., et al. (2003) · Leukemia · doi:10.1038/sj.leu.2403135 · Cited by 1,284
Acute promyelocytic leukemia: from highly fatal to highly curable
Wang, Z.-Y., & Chen, Z. (2008) · Blood · doi:10.1182/blood-2007-07-102798 · Cited by 1,277
van Dongen, J., Macintyre, E., Gabert, J., Delabesse, E., Rossi, V, Saglio, G., Gottardi, E., Rambaldi, A., Dotti, G., Griesinger, F., et al. (1999) · Leukemia · doi:10.1038/sj.leu.2401592 · Cited by 1,169
Self-citationSanz, M. A., Grimwade, D., Tallman, M. S., Lowenberg, B., Fenaux, P., Estey, E. H., Naoe, T., Lengfelder, E., Büchner, T., Döhner, H., et al. (2009) · Blood · doi:10.1182/blood-2008-04-150250 · Cited by 947
Self-citationUnited States Multicenter Study of Arsenic Trioxide in Relapsed Acute Promyelocytic Leukemia
Soignet, S. L., Frankel, S. R., Douer, D., Tallman, M. S., Kantarjian, H., Calleja, E., Stone, R. M., Kalaycio, M., Scheinberg, D. A., Steinherz, P., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.18.3852 · Cited by 826 · cited 1×
“A genetic diagnosis could be established by detection of the PML-RARA fusion gene by means of reverse-transcriptase–polymerase-chain-reaction (RT-PCR) assay,28,29 demonstration of the t(15;17) translocation by means of conventional karyotyping or fluorescence in situ hybridization (FISH),30 or evidence of a microspeck…”
Research works printed but not linked: 3
- Zhang P, 1996, Chin J Hematol, 17, 58
- Sanz MA, 2000, Blood, 96, 1247
- Grimwade D, 2000, Blood, 96, 1297
Cited by
Items 801–900 of 1,000
Breccia, M., Cicconi, L., & Lo‐Coco, F. (2014) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000023 · Cited by 8
Self-citationOligoclonality and new agent evaluation in acute lymphoblastic leukaemia
Gaynon, P. S., & Sun, W. (2016) · British Journal of Haematology · doi:10.1111/bjh.14143 · Cited by 8
“…66% OS in 18 months (Soignet et al, 2001) When compared to ATRA+chemotherapy, ATRA+ATO showed significantly improved EFS (P = 0 02) and OS (P = 0 02) (Lo-Coco et al, 2013) ALL, acute lymphoblastic leukaemia; AML, acute myeoid leukaemia; APL, acute promyelocytic leukaemia; ATO, arsenic trioxide;…”
ResultCombined chemotherapy for acute promyelocytic leukemia: a meta-analysis
Li, X., Wang, C., Chen, G., Ji, B., & Xu, Y. (2017) · Hematology · doi:10.1080/10245332.2017.1318239 · Cited by 8
Using genomics to define pediatric blood cancers and inform practice
Rau, R. E., & Loh, M. L. (2018) · Hematology · doi:10.1182/asheducation-2018.1.286 · Cited by 8
Can allogeneic hematopoietic cell transplant cure therapy-related acute leukemia?
Madanat, Y. F., & Gerds, A. T. (2019) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2019.02.011 · Cited by 8
Hematopoietic stem cell transplantation for pediatric acute promyelocytic leukemia in Japan
Yamamoto, S., Tomizawa, D., Kudo, K., Hasegawa, D., Taga, T., Yanada, M., Kondo, T., Nakazawa, Y., Eto, T., Inoue, M., et al. (2020) · Pediatric Blood & Cancer · doi:10.1002/pbc.28181 · Cited by 8
Oral Arsenic-Containing Qinghuang Powder: A Potential Drug for Myelodysplastic Syndromes
Ming, J., Liu, W., Xiao, H., Xu, Y., Ma, R., & Hu, X. (2020) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-020-3254-9 · Cited by 9
Interplay of Ubiquitin-Like Modifiers Following Arsenic Trioxide Treatment
Robert, C. R., McManus, F. P., Lamoliatte, F., & Thibault, P. (2020) · Journal of Proteome Research · doi:10.1021/acs.jproteome.9b00807 · Cited by 8
Maucort, C., Giorgio, A. D., Azoulay, S., & Duca, M. (2020) · ChemMedChem · doi:10.1002/cmdc.202000251 · Cited by 10
Shenoy, S. M., Vitantonio, T. A. D., Plitt, A., Pérez-Johnston, R., Gutierrez, J., Knorr, D. A., Stein, E. M., Liu, J. E., & Feldman, S. A. (2021) · Cardio-Oncology · doi:10.1186/s40959-021-00124-9 · Cited by 8
“10 mg/kg and ATRA 25 mg/m2 (per the Lo Coco protocol) without complication [2].”
Zhu, H., Hu, J., & Gu, X. (2016) · Journal of Global Oncology · doi:10.1200/jgo.2016.005405 · Cited by 8
“A landmark study showed that APL can be cured without chemotherapy using arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA).(1) The former can even be substituted with oral arsenic (the Realgar-Indigo naturalis formula), allowing a largely home-based treatment protocol.”
BackgroundSobas, M., Czyż, A., Montesinos, P., Armatys, A., Helbig, G., Hołowiecka, A., Pluta, A., Zarzycka, E., Piątkowska‐Jakubas, B., Majcherek, M., et al. (2019) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2019.09.616 · Cited by 8
Bourgeois, W., Armstrong, S. A., & Heikamp, E. (2024) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041637 · Cited by 9
Arsenic Trioxide and Tretinoin (AsO/ATRA) for Acute Promyelocytic Leukemia (APL)
Damery, E., Solimando, D. A., & Waddell, J. A. (2016) · Hospital Pharmacy · doi:10.1310/hpj5108-628 · Cited by 7
Bidikian, A., Bewersdorf, J. P., Kewan, T. Z., Stahl, M. F., & Zeidan, A. M. (2024) · Cancers · doi:10.3390/cancers16234092 · Cited by 10
Research progress on gene mutations and drug resistance in leukemia
Ma, X., Xu, J., Wang, Y., Fleishman, J. S., Bing, H., Yu, B., Li, Y., Bo, L., Zhang, S., Chen, Z., et al. (2024) · Drug Resistance Updates · doi:10.1016/j.drup.2024.101195 · Cited by 10
Wang, Y., Kinose, Y., Kasuya, K., Koizumi, M., Shimizu, A., Nakamura, K., Toda, A., Kawano, M., Kodama, M., Hashimoto, K., et al. (2025) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-24-0490 · Cited by 7
Lebon, D., Rocha, A. D., Cassinat, B., Heiblig, M., Bertoli, S., Bonmati, C., Zilliox, A., Laloi, M., Berthon, C., Duployez, N., et al. (2025) · Leukemia · doi:10.1038/s41375-025-02663-x · Cited by 7
Reprogramming SUMO-primed ubiquitylation: opportunities in oncology and neurology
Gotthardt, G., Keiten‐Schmitz, J., & Müller, S. P. (2025) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2025.09.002 · Cited by 8
PML/RARα Destabilization by Hyperthermia: A New Model for Oncogenic Fusion Protein Degradation?
Wu, H.-C., Rérolle, D., & de Thé, H. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0071 · Cited by 7
“The combination of first-line ATRA and ATO has now become the gold standard of APL therapy and cures more than 95% of patients (3).”
BackgroundIland, H. J., Russell, N. H., Dillon, R. J., Schuh, A. C., Tedjaseputra, A., Wei, A. H., Khwaja, A., Knapper, S., Lane, S., Reynolds, J., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022007126 · Cited by 8
“Total cohort 37 (100) Age (y) 37 (100) 43 (1-73)”
Singh, B., Pahuja, I., Yadav, P., Shaji, A., Chaturvedi, S., Ranganathan, A., Dwivedi, V. P., & Das, G. (2023) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiad460 · Cited by 7
Bercier, P., & de Thé, H. (2024) · Cancers · doi:10.3390/cancers16071351 · Cited by 9
“Indeed, the ATRA + ATO combination increases the number of CR, decreases the time necessary to reach remission, and increases EFS [34,54–56].”
BackgroundResultSingle-cell multiomics reveals a gene regulatory circuit driving leukemia cell differentiation
Tian, X., Zhang, L., Tang, Y., Xiang, G., Wang, Z., Zhu, P., Yu, S., Jiang, F., Wang, S., Wang, J., et al. (2025) · Oncogene · doi:10.1038/s41388-025-03309-z · Cited by 7
“Given the strong differentiation phenotype of APL in vitro and in vivo [12, 13], we proposed that its induced differentiation trajectory could serve as an ideal model to identify key differentiation drivers in a leukemic cell context and facilitate fi nding the potential therapeutic targets.”
Zhang, X., Zhang, Q., Dahlström, J., Tran, A. N., Yang, B., Gu, Z., Ghaderi, M., Porwit‐MacDonald, A., Jia, J., Derolf, Å. R., et al. (2014) · Leukemia · doi:10.1038/leu.2014.113 · Cited by 7
Winterfield, J. R., & Milan, D. J. (2015) · HeartRhythm Case Reports · doi:10.1016/j.hrcr.2015.07.010 · Cited by 7
“However, dose-limiting toxicity in the form of druginduced QT prolongation limits its use in a significant percentage of patients.(1) Preclinical models of long QT syndrome (LQTS) have demonstrated that glucocorticoids can significantly shorten the duration of the cardiac action potential.”
BackgroundTailored Approaches to Induction Therapy for Acute Promyelocytic Leukemia
DeAngelo, D. J. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.4761 · Cited by 7
Irreversibility of arsenic trioxide induced PML/RARα fusion protein solubility changes
Maimaitiyiming, Y., Shao, Y., Chen, W. Z., Jiang, Y. H., Bu, N., Li, Y., Wang, Q. Q., Lu, X. Y., & Naranmandura, H. (2019) · Metallomics · doi:10.1039/c9mt00220k · Cited by 7
Targeting differentiation blockade in AML: New hope from cell-surface-based CRISPR screens
Su, R. J., Qing, Y., & Chen, J. (2021) · Cell stem cell · doi:10.1016/j.stem.2021.03.006 · Cited by 7
Acute Promyelocytic Leukemia: Update on Risk Stratification and Treatment Practices
Salhotra, A., & Mei, M. G. (2021) · Cancer treatment and research · doi:10.1007/978-3-030-78311-2_3 · Cited by 7
Intensive chemotherapy perturbs heart rate variability in children with cancer
Çakan, P., Yıldız, S., Akyay, A., & Öncül, Y. (2021) · Neurophysiologie Clinique · doi:10.1016/j.neucli.2021.11.001 · Cited by 7
Molinaro, A., Zanta, D., Moleti, M. L., Giona, F., Conter, V., Rizzari, C., Biondi, A., & Testi, A. M. (2022) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2022.027 · Cited by 7
Li, H., Niu, T., Huang, J., Xie, L., He, C., Li, J., Xiang, B., Cui, X., Wu, Y., Tang, Y., et al. (2022) · International Journal of Hematology · doi:10.1007/s12185-022-03515-5 · Cited by 7
Skoczyńska, A., & Skoczyńska, M. (2022) · BioMed Research International · doi:10.1155/2022/8030931 · Cited by 7
Illangeswaran, R. S. S., Jebanesan, D. Z. P., Sivakumar, K. K., Vidhyadharan, R. T., Rajamani, B. M., Arthur, N. B. J., David, E. K., Velayudhan, S. R., Mathews, V., & Balasubramanian, P. (2023) · Leukemia Research · doi:10.1016/j.leukres.2023.107054 · Cited by 8
Epidemiology and early mortality patterns of acute promyelocytic leukemia in the United States
Sharma, A., Yang, J., & Singh, V. (2023) · Annals of Hematology · doi:10.1007/s00277-023-05154-0 · Cited by 7
Luo, J.-S., Zhang, X., Huang, D.-P., Chen, Y.-Q., Wan, W., Mai, H., Chen, H., Wen, H., Liu, R., Chen, G.-H., et al. (2023) · Annals of Hematology · doi:10.1007/s00277-023-05270-x · Cited by 7
Josa‐Culleré, L., Galan, S. R. G., Cogswell, T. J., Jackson, T., Jay‐Smith, M., Mola, L., Greaves, C. R., Carter, T. S., Madden, K. S., Trott, S., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115509 · Cited by 7
Quartin, E., Rosa, S. C., Antón, S. G., Mosteo, L., Francisco, V., Duarte, D., Celso, C. L., das Neves, R. P., & Ferreira, L. (2024) · Bioactive Materials · doi:10.1016/j.bioactmat.2023.12.017 · Cited by 10
Thrombosis in Myeloid Malignancies: From CHIP to AML
Borsellino, B., Bravo‐Pérez, C., Visconte, V., & Guarnera, L. (2024) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/011871529x307253240530060107 · Cited by 7
Engaging a senescent response to cure leukemia
Bourdeau, V., & Ferbeyre, G. (2014) · Nature Medicine · doi:10.1038/nm.3469 · Cited by 7
A phase II study of arsenic trioxide in patients with relapsed or refractory malignant lymphoma
Zhao, H., Sun, G., Kong, D., Zhang, Y., Shi, W., Zhao, M., Hong, L., & Qiao, Z. (2015) · Medical Oncology · doi:10.1007/s12032-015-0526-x · Cited by 7
“In a recent publication examining the role of ATO in the treatment of acute promyelocytic leukemia, 2-year event-free survival rates were 97 % in the ATO-treated group and 86 % in the standard chemotherapy group [5].”
BackgroundWang, Y., He, P., Qi, J., LIU, Y.-F., & Zhang, M. (2015) · Biomedical Reports · doi:10.3892/br.2015.466 · Cited by 7
Massive pulmonary embolism at the onset of acute promyelocytic leukemia
Sorà, F., Chiusolo, P., & Laurenti, L. (2016) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2016.027 · Cited by 7
Wu, F., Wu, D., Ren, Y., Duan, C., Chen, S., & Xu, A. (2016) · Oncotarget · doi:10.18632/oncotarget.10118 · Cited by 8
“2013 [12] Europe 2007–2010 156 76/80 44.”
BackgroundEffects of LG268 on Cell Proliferation and Apoptosis of NB4 Cells
Xu, T., Zhong, L., Gan, L., Xiao, C., Shan, Z., Yang, R., Song, H., Li, L., & Liu, B. (2016) · International Journal of Medical Sciences · doi:10.7150/ijms.15507 · Cited by 7
“APL is a malignancy that is highly curable using targeted therapies [21].”
BackgroundRetsas, S. (2016) · Geological Society London Special Publications · doi:10.1144/sp452.5 · Cited by 7
“%) remission (Chen & Chen 2013; Lo-Coco et al. 2013).”
Gaut, D. L., Sasine, J. P., & Schiller, G. J. (2018) · Leukemia Research Reports · doi:10.1016/j.lrr.2018.04.005 · Cited by 9
Optimal Measurable Residual Disease Testing for Acute Myeloid Leukemia
Xiao, W., Petrova‐Drus, K., & Roshal, M. (2019) · Surgical pathology clinics · doi:10.1016/j.path.2019.03.009 · Cited by 7
Evaluation of the target genes of arsenic trioxide in pancreatic cancer by bioinformatics analysis
Zhou, C., Gong, L., Liao, R., Weng, N., Feng, Y., Dong, Y., Zhu, H., Zhao, Y., Zhang, Y., Zhu, Q., et al. (2019) · Oncology Letters · doi:10.3892/ol.2019.10889 · Cited by 7
“Combined treatment with retinoic acid (RA) and ATO has been demonstrated to be curative for the majority of patients with APL (7-9).”
BackgroundZhang, X., Liu, L., Yao, Y., Gong, S., Wang, M., Xi, J., Chen, L.-M., Wei, S., Zhang, H., Zhao, C., et al. (2020) · Trials · doi:10.1186/s13063-019-3983-2 · Cited by 7
The History of the Chemo-Free Model in the Treatment of Acute Promyelocytic Leukemia
Zhu, H. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.592996 · Cited by 7
Acute promyelocytic leukemia (APL) in very old patients: real-life behind protocols
Rosati, S., Gurnari, C., Breccia, M., Carmosino, I., Scalzulli, E., Montefusco, E., Perrone, S., Annibali, O., Martini, V., Trapè, G., et al. (2021) · Acta Oncologica · doi:10.1080/0284186x.2021.1971291 · Cited by 7
“AIDA regimen [29], consisting of oral ATRA (45mg/m(2)/d) until hematologic CR and intravenous Idarubicin (IDA) (12mg/m(2)/d) given on days 2,4,6,8; ATRAþATO regimen according to APL 0406 trial [3], consisting of oral ATRA (45mg/m(2)/d) and ATO (0.”
MethodSelf-citationMiltiadous, O., Petrova‐Drus, K., Kaicker, S. M., Mathew, S., Kluk, M., Geyer, J. T., Rodriguez-Sanchez, I., Bouvier, N., Inghirami, G. G., Stieglitz, E., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004966 · Cited by 7
The pharmacokinetics of therapeutic arsenic trioxide in acute promyelocytic leukemia patients
Ghiuzeli, C. M., Stýblo, M., Saunders, J., Calabro, A. R., Budman, D. R., Allen, S. L., Devoe, C., & Dhingra, R. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1978084 · Cited by 8
“of care in low/intermediate-risk APL patients [5].”
Döhner, K., Paschka, P., & Döhner, H. (2015) · Der Internist · doi:10.1007/s00108-014-3596-5 · Cited by 10
Self-citationNaymagon, L., Najfeld, V., Teruya‐Feldstein, J., Jamal, S. M. E., & Mascarenhas, J. O. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-56738-1.00008-7 · Cited by 7
Yanada, M., Matsuda, K., Ishii, H., Fukuda, T., Ozeki, K., Ota, S., Tashiro, H., Uchida, N., Kako, S., Doki, N., et al. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.09.021 · Cited by 7
Minimal Coexpression of CD34+/CD56+ in Acute Promyelocytic Leukemia Is Associated With Relapse
Maenhout, T. M., Moreau, E., Haute, I. V., Desmet, S., & Deeren, D. (2015) · American Journal of Clinical Pathology · doi:10.1309/ajcpbs3w1rjdgpzu · Cited by 7
Mamorska-Dyga, A., Wu, J., Khattar, P., Ronny, F. M. H., Islam, H. K., Seiter, K. P., & Liu, D. (2016) · Stem Cell Investigation · doi:10.21037/sci.2016.03.02 · Cited by 7
“Arsenic trioxide (ATO) was added on day 10 according to the reported regimen for clinically low-risk APL (16).”
MethodSawhney, S., Holtzman, N. G., Davis, D. L., Kaizer, H., Giffi, V. S., Emadi, A., & Koka, R. (2017) · Clinical Case Reports · doi:10.1002/ccr3.1212 · Cited by 7
“with all-trans retinoic acid (ATRA) and arsenic trioxide which she tolerated well without any complications [1].”
BackgroundAcute Promyelocytic Leukemia and HIV: Case Reports and a Review of the Literature
Kunitomi, A., Hasegawa, Y., lmamura, J., Yokomaku, Y., Tokunaga, T., Miyata, Y., Iida, H., & Nagai, H. (2019) · Internal Medicine · doi:10.2169/internalmedicine.1662-18 · Cited by 7
“Recently, it has also been shown to be effective in patients with newly diagnosed APL as induction therapy (19, 20).”
BackgroundLessons taught by acute promyelocytic leukemia cure
de Thé, H. (2015) · The Lancet · doi:10.1016/s0140-6736(15)61278-8 · Cited by 7
Alhajahjeh, A. A., Stahl, M. F., Kim, T. K., Kewan, T. Z., Stempel, J. M., Zeidan, A. M., & Bewersdorf, J. P. (2025) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2025.2483855 · Cited by 7
“Arsenic trioxide (ATO) is very effective in treating APL but failed to show benefit in other types of AML [154].”
Zaza, A., Zardo, G., Banella, C., Tucci, S., Marinis, E. D., Gentile, M., Travaglini, S., Divona, M., Ottone, T., Castelli, G., et al. (2025) · Leukemia · doi:10.1038/s41375-025-02738-9 · Cited by 7
“In resistant patients, hematologic stem cell transplantation (allo-HSCT) is the only curative approach [3, 11].”
Self-citationA tour of leukemia progress in 2025, viewed through the MD Anderson leukemia research lens
Kantarjian, H. M., Borthakur, G. M., Daver, N. G., Dinardo, C. D., Garcia‐Manero, G., Issa, G. C., Jabbour, E. J., Jain, N., Kadia, T. M., Loghavi, S., et al. (2025) · Cancer · doi:10.1002/cncr.70113 · Cited by 8
Early mortality in patients with acute promyelocytic leukemia: a systematic review and meta-analysis
Chean, D., Kemp, H., Fodil, S., Darmon, M., Azoulay, É., & Dupont, T. (2025) · Critical Care · doi:10.1186/s13054-025-05743-7 · Cited by 8
Wáng, Y. X. J., & Xiao, F. (2015) · PubMed · doi:10.3978/j.issn.2223-4292.2015.03.10 · Cited by 6
“Recently, a phase 3, multicenter trial comparing ATRA plus chemotherapy versus ATRA plus arsenic trioxide showed ATRA plus arsenic trioxide was superior to ATRA plus chemotherapy in the treatment of patients with lowto-intermediate-risk APL (72).”
BackgroundNiu, M., Shen, Y., Qi, J., Liu, X., Sang, W., Wu, Q., Cao, J., Chen, W., Yao, Y., & Xu, K. (2017) · Annals of Hematology · doi:10.1007/s00277-017-3093-8 · Cited by 6
A Proteomic Platform Enables to Test for AML Normalization In Vitro
Meier, S. M., Neuditschko, B., Janker, L., Gerner, M. C., Schmetterer, K. G., Reichle, A., & Gerner, C. (2022) · Frontiers in Chemistry · doi:10.3389/fchem.2022.826346 · Cited by 6
“In contrast to cytotoxic anticancer chemotherapy in which the therapeutic agents are administered at maximum tolerable doses, ATO + ATRA is administered in a low-dose treatment regime over a prolonged time period (Lo-Coco et al., 2013; Burnett et al., 2015; Heudobler et al., 2019b).”
BackgroundMethodInfluentialEpidemiology of de novo Acute Myeloid Leukemia in Kuwait per the 2016 WHO Classification
Alshemmari, S., Almazyad, M. J., Ram, M., John, L. M., & Alhuraiji, A. (2022) · Medical Principles and Practice · doi:10.1159/000524641 · Cited by 8
Dubey, S., Mishra, N., Goswami, N., Siddiqui, M. Q., & Varma, A. K. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.11.022 · Cited by 6
Risk factors and remaining challenges in the treatment of acute promyelocytic leukemia
Yokoyama, Y. (2024) · International Journal of Hematology · doi:10.1007/s12185-023-03696-7 · Cited by 6
“The combination therapy of ATRA and ATO (ATRA + ATO) has further improved the prognosis of APL, and now APL with initial white blood cell count (WBC) 10,000/μL (standard-risk APL) has become a curable disease by treat-ment with ATRA + ATO [14–16].”
Qu, M., He, Q., Bao, H., Ji, X., Shen, T., Barkat, M. Q., Wu, X., & Zeng, L. (2024) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2024.02.011 · Cited by 6
“Clinically, the combination of all-trans retinoic acid (ATRA) and ATO has been widely applied in acute promyelocytic leukemia (APL) treatment [2,3].”
BackgroundMohty, R., Reljic, T., Yassine, F., Kettaneh, C., Al-Husni, D., Keller, K., Badar, T., Murthy, H. S., Foran, J. M., Kumar, A., et al. (2024) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2024.03.024 · Cited by 6
Iland, H. J., Reynolds, J., Boddy, A. V., Schultz, H. B., Khoo, L., Fleming, S. A., Lane, S., Weber, N., Gasiorowski, R., Armytage, T., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024015397 · Cited by 8
“32 Chemotherapy-free protocols based on ATRA and arsenic are now standard-of-care for patients with SR APL, 10,11,16 and combinations of arsenic, ATRA, and limited anthracycline or gem-tuzumab ozogamicin are also emerging as the treatment of choice for patients with HR APL.”
InfluentialDiagnostic and Therapeutic Implications of the SUMOylation Pathway in Acute Myeloid Leukemia
Chatzikalil, E., Arvanitakis, K., Filippatos, F., Diamantopoulos, P. T., Koufakis, T., & Solomou, E. E. (2025) · Cancers · doi:10.3390/cancers17040631 · Cited by 6
A new target for differentiation therapy in AML
Ma, P., Song, W., & Hess, J. L. (2016) · Cell Research · doi:10.1038/cr.2016.130 · Cited by 7
Hashimoto, Y., Hatayama, Y., Kojima, N., Morishita, S., Matsumoto, S., Hosoda, Y., Hara, A., & Motokura, T. (2016) · Europe PMC (PubMed Central) · Cited by 6
Hecht, A., Doll, S., Altmann, H., Nowak, D., Lengfelder, E., Röllig, C., Ehninger, G., Spiekermann, K., Hiddemann, W., Weiß, C., et al. (2017) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2017.08.095 · Cited by 6
“4 (15) 3 (13) 7 (27) 3 (13) 2 (8) 1 (4)”
BackgroundSelf-citationTao, S., Wang, C., Chen, Y., Deng, Y., Song, L., Shi, Y., Ling, L., Ding, B., He, Z., & Yu, L. (2018) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2018.1504941 · Cited by 6
Danthala, M., Golamari, K. R., Seshachalam, A., Mikkilineni, A., Chappidi, S., Mekala, M. B., Elangovan, V., & Chinnakali, P. (2020) · JCO Global Oncology · doi:10.1200/go.20.00226 · Cited by 7
“Standard induction and consolidation for low- to intermediate-risk APL involves all-trans-retinoic-acid (ATRA) plus arsenic trioxide (ATO).(9,10) Adoption of the same approach in patients with high-risk APL (defined as those with an initial WBC count .”
BackgroundLuo, S., Tian, J., Sun, X., Wu, F., Liu, Y., Wan, W., She, Z., & Wen, C. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/8314176 · Cited by 7
“In addition, the GIMEMA-SAL-AMLSG APL0406 trial reported QTc interval prolongation in 16% of patients in the ATRA+ATO group [46].”
MethodMolica, M., & Perrone, S. (2022) · Expert Review of Hematology · doi:10.1080/17474086.2022.2140137 · Cited by 6
“Historically, APL was the first to be treated with chemo-free target therapy with ATRA and trioxide of arsenic with 97% EFS [6].”
BackgroundHuang, Q., Zhang, Y., & Zheng, M. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1342671 · Cited by 6
Schnetzke, U., Fix, P., Spies-Weisshart, B., Schrenk, K. G., Glaser, A., Fricke, H., Rosée, P. G. L., Hochhaus, A., & Scholl, S. (2014) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-014-1666-7 · Cited by 6
Yamamoto, M., Okada, K., Akiyama, H., Kurosu, T., & Miura, O. (2014) · Molecular and Clinical Oncology · doi:10.3892/mco.2014.476 · Cited by 7
Time to abandon traditional chemotherapy for acute promyelocytic leukaemia?
Ravandi, F., & Kantarjian, H. M. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00210-7 · Cited by 6
Emerging new anticancer biological therapies in 2013 (haematological malignancies)
Plawny, L., & Ries, F. (2014) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000079 · Cited by 7
Non‐inferiority trials: No better? No worse? No change? No pain?
Hills, R. K. (2017) · British Journal of Haematology · doi:10.1111/bjh.14504 · Cited by 6
Current First- and Second-Line Treatment Options in Acute Promyelocytic Leukemia
Massaro, F., Molica, M., & Breccia, M. (2016) · International Journal of Hematologic Oncology · doi:10.2217/ijh-2016-0010 · Cited by 6
Self-citationLengfelder, E., Görlich, D., Nowak, D., Spiekermann, K., Haferlach, C., Krug, U. O., Kreuzer, K., Braess, J., Schliemann, C., Lindemann, H., et al. (2017) · European Journal Of Haematology · doi:10.1111/ejh.12994 · Cited by 6
Ghavamzadeh, A., Jalili, M., Rostami, S., Yaghmaie, M., Aliabadi, L. S., Mousavi, S. A., Vaezi, M., Fumani, H. K., Jahani, M., & Alimoghaddam, K. (2018) · Leukemia Research · doi:10.1016/j.leukres.2018.01.019 · Cited by 6
Arsenic-Based Anticancer-Combined Therapy: Novel Mechanism Inducing Apoptosis of Cancer Cells
Ota, A., Wahiduzzaman, M., & Hosokawa, Y. (2018) · InTech eBooks · doi:10.5772/intechopen.74824 · Cited by 7
Modeling dynamics and alternative treatment strategies in acute promyelocytic leukemia
Júnior, G. H. Y., Fassoni, A. C., Mello, L. F., & Rego, E. M. (2019) · PLoS ONE · doi:10.1371/journal.pone.0221011 · Cited by 7
Eradicating the Roots: Advanced Therapeutic Approaches Targeting Breast Cancer Stem Cells
He, L., Yu, A., Deng, L., & Zhang, H. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200317132949 · Cited by 6
Case 10-2020: An 83-Year-Old Man with Pancytopenia and Acute Renal Failure
Sykes, D. B., Zhang, E. W., Leaf, R. K., Nardi, V., & Turbett, S. E. (2020) · New England Journal of Medicine · doi:10.1056/nejmcpc1916250 · Cited by 7
Reed, D. R., Sen, J. M., Pierce, E. J., Elsarrag, R. Z., & Keng, M. K. (2020) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155220918006 · Cited by 7
“In clinical trials with gilteritinib, risk of differentiation syndrome (3%) was low relative to the treatment settings of acute promyelocytic leukemia or the new IDH inhibitors for AML; however, the syndrome’s potential severity and propensity for rapid clinical deterioration requires patients, caregivers, and medical…”
BackgroundThe Case for Abandoning Induction Chemotherapy
Pollyea, D. A. (2017) · The Hematologist · doi:10.1182/hem.v14.3.7298 · Cited by 7
Maintenance therapy for acute myeloid leukemia: sustaining the pursuit for sustained remission
Shallis, R. M., & Podoltsev, N. A. (2020) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000637 · Cited by 6
Metadata
- Authors
- Lo-Coco, F., Avvisati, G., Vignetti, M., Thiede, C., Orlando, S. M., Iacobelli, S., Ferrara, F., Fazi, P., Cicconi, L., Di Bona, E., Specchia, G., Sica, S., Divona, M., Levis, A., Fiedler, W., Cerqui, E., Breccia, M., Fioritoni, G., Salih, H. R., Cazzola, M., Melillo, L., Carella, A. M., Brandts, C. H., Morra, E., von Lilienfeld-Toal, M., Hertenstein, B., Wattad, M., Lübbert, M., Hänel, M., Schmitz, N., Link, H., Kropp, M. G., Rambaldi, A., La Nasa, G., Luppi, M., Ciceri, F., Finizio, O., Venditti, A., Fabbiano, F., Döhner, K., Sauer, M., Ganser, A., Amadori, S., Mandelli, F., Döhner, H., Ehninger, G., Schlenk, R. F., & Platzbecker, U.
- ORCID
- Avvisati, Giuseppe
- Vignetti, Marco
- Thiede, Christian
- Iacobelli, Simona
- Ferrara, Felicetto
- Fazi, Paola
- Cicconi, Laura
- Specchia, Giorgina
- Sica, Simona
- Fiedler, Walter
- Breccia, Massimo
- Salih, Helmut R.
- Cazzola, Mario
- Melillo, Lorella
- Carella, Angelo M.
- Brandts, Christian H.
- Hertenstein, Bernd
- Lübbert, Michael
- Hänel, Matthias
- Schmitz, Norbert
- Link, Hartmut
- Rambaldi, Alessandro
- Luppi, Mario
- Ciceri, Fabio
- Finizio, Olimpia
- Venditti, Adriano
- Döhner, Konstanze
- Ganser, Arnold
- Amadori, Sergio
- Döhner, Hartmut
- Ehninger, Gerhard
- Schlenk, Richard F.
- Platzbecker, Uwe
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-07-11
- Volume
- 369
- Issue
- 2
- Pages
- 111-121
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2129338773
- Cited by
- 1,611
- References
- 42
- Citations by year
- 2026: 83 · 2025: 89 · 2024: 132 · 2023: 144 · 2022: 110 · 2021: 147 · 2020: 137 · 2019: 125 · 2018: 122 · 2017: 107 · 2016: 117 · 2015: 144 · 2014: 119 · 2013: 33
- FWCI
- 61.62
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- cc-by
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- UNICA IRIS Institutional Research Information System (University of Cagliari) (submittedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Keywords
- acute promyelocytic leukemia, all-trans retinoic acid, arsenic trioxide, idarubicin, induction therapy, consolidation therapy, maintenance therapy, event-free survival, overall survival, complete remission, hematologic toxicity, hepatotoxicity
- MeSH terms
- Arsenic Trioxide, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Arsenicals, Female, Humans, Male, Middle Aged, Neutropenia, Oxides, Thrombocytopenia, Tretinoin, Leukemia, Promyelocytic, Acute, Disease-Free Survival, Young Adult, Maintenance Chemotherapy, Induction Chemotherapy, Consolidation Chemotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.